Trial Profile
A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs SRA 737 (Primary) ; Cisplatin; Gemcitabine
- Indications Anal cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Rectal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Sierra Oncology
- 15 Nov 2022 Results of safety profile, recommended phase 2 dose (RP2D), pharmacokinetics profile, and clinical activity of SRA737,published in the Clinical Cancer Research
- 23 Sep 2020 Status changed from active, no longer recruiting to completed.
- 22 May 2020 This trial has been completed in Austria according to European Clinical Trials Database record.